Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use. Objective: To provide consensus statements from the Biosimilar Working Group about the use of biosimilars in patients with psoriasis. Methods: A semi...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Arnon D. Cohen, MD, MPH, PhD, Ronald Vender, MD, FRCPC, Luigi Naldi, MD, Robert E. Kalb, MD, Tiago Torres, MD, PhD, Murlidhar Rajagopalan, MD, Joelle van der Walt, PhD, Lluís Puig, MD (Hon), PhD, Helen S. Young, MB ChB, PhD, FRCP
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Elsevier 2020-12-01
Reeks:	JAAD International
Onderwerpen:	biosimilars interchangeability International Psoriasis Council psoriasis switching tumor necrosis factor inhibitors
Online toegang:	http://www.sciencedirect.com/science/article/pii/S2666328720300523

Gelijkaardige items

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
door: Zhou X, et al.
Gepubliceerd in: (2021-07-01)

Biosimilars
door: Emel Bülbül Başkan
Gepubliceerd in: (2022-04-01)

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
door: Alexandra Azevedo, et al.
Gepubliceerd in: (2018-09-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
door: Changkun Li, et al.
Gepubliceerd in: (2023-12-01)

Portuguese Position Paper on the Use of Biosimilars in Psoriasis
door: Tiago Torres, et al.
Gepubliceerd in: (2016-09-01)

Psoriasis vulgaris with fibrokeratoma from pityriasis amiantacea
door: Chihiro Shiiya, MD, et al.
Gepubliceerd in: (2017-05-01)

Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in DenmarkCapsule Summary
door: Cæcilie Bachdal Johansen, MD, et al.
Gepubliceerd in: (2022-06-01)

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
door: Megna M, et al.
Gepubliceerd in: (2022-07-01)

Psoriasis coxsackium
door: Daniel W. Cole, MD, et al.
Gepubliceerd in: (2022-07-01)

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
door: Rachel C. Ruda, et al.
Gepubliceerd in: (2023-12-01)

A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs
door: Rebecca Reese, et al.
Gepubliceerd in: (2024-12-01)

Mild-to-moderate severity of psoriasis may be assessed remotely based on photographs and self-reported extent of skin involvementCapsule Summary
door: Zarqa Ali, MD, PhD, et al.
Gepubliceerd in: (2023-06-01)

Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumabCapsule Summary
door: Tamara Gracia Cazaña, MD, PhD, et al.
Gepubliceerd in: (2024-09-01)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
door: Kanako Tsunoda, MD, PhD, et al.
Gepubliceerd in: (2024-09-01)

Ustekinumab Biosimilars
door: Elena Carmona-Rocha, et al.
Gepubliceerd in: (2024-11-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
door: A. A. Soldatov, et al.
Gepubliceerd in: (2019-03-01)

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
door: Alan Menter
Gepubliceerd in: (2023-10-01)

Late-onset development of psoriasis in Japan: a population-based cohort studyCapsule Summary
door: Haruka Goto, MD, et al.
Gepubliceerd in: (2021-03-01)

On the Regulatory Approval Pathway of Biosimilar Products
door: Jun Wang, et al.
Gepubliceerd in: (2012-03-01)

Sociodemographic factors have very little influence on adherence to topical drugs in patients with psoriasis
door: Mathias Tiedemann Svendsen, MD, PhD, et al.
Gepubliceerd in: (2024-12-01)

Prognostic implications of high-sensitivity cardiac troponin in patients with suspected myocardial infarction with or without psoriasis
door: Sanaz A. Guldmann, MD, DPhil, et al.
Gepubliceerd in: (2023-06-01)

Among psoriasis patients in Flanders, Belgium, a third has sexual dysfunction and almost half depression symptoms
door: Roel Van Overmeire, PhD, et al.
Gepubliceerd in: (2025-02-01)

Facial psoriasis in a mask-like distribution
door: Cameron M.B. Zachary, MS, et al.
Gepubliceerd in: (2021-01-01)

Injection site reactions due to the use of biologics in patients with psoriasis: A retrospective study
door: Yun Kyung Jang, MD, et al.
Gepubliceerd in: (2023-03-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
door: Т. V. Korotaeva, et al.
Gepubliceerd in: (2018-12-01)

Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
door: Mohammed Alqahtani, et al.
Gepubliceerd in: (2024-11-01)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
door: Cohen SB, et al.
Gepubliceerd in: (2023-10-01)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
door: Yuliya Lytvyn, PhD, et al.
Gepubliceerd in: (2022-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
door: João Pedro Fernandes, et al.
Gepubliceerd in: (2015-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
door: João Pedro Fernandes, et al.
Gepubliceerd in: (2015-01-01)

Successful treatment of palmoplantar psoriasis with chemical peeling and gentian violet
door: Jeffrey A. Bubley, MD, et al.
Gepubliceerd in: (2021-11-01)

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
door: Steven R. Feldman, et al.
Gepubliceerd in: (2024-12-01)

Biosimilars, the journey has begun
door: Alba Martos-Rosa, et al.
Gepubliceerd in: (2015-01-01)

A pustular psoriasis flare treated with calcium supplementation
door: Laure Masson, MD, et al.
Gepubliceerd in: (2021-06-01)

Nanotomography of lesional skin using electron microscopy reveals cytosolic release of nuclear DNA in psoriasis
door: Eric Lindberg, PhD, et al.
Gepubliceerd in: (2021-03-01)

The Problem of Anti-Cytokine Therapy in Psoriasis Patients
door: Ramina K. Keshileva, PhD
Gepubliceerd in: (2012-09-01)

Cardiovascular Complications During Delivery Hospitalization in Patients With Psoriasis
door: Ankit Agrawal, MD, et al.
Gepubliceerd in: (2025-02-01)

Onset of rupioid psoriasis after vasodilatory regimen initiation in a patient with pulmonary arterial hypertension
door: Uros Rakita, MSc, et al.
Gepubliceerd in: (2021-06-01)

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
door: Ronald Vender, MD, et al.
Gepubliceerd in: (2022-09-01)

Societal impact for patients with psoriasis: A nationwide Swedish register studyCapsule Summary
door: Henrike Häbel, PhD, et al.
Gepubliceerd in: (2021-06-01)